Repligen Corporation $RGEN Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group trimmed its stake in Repligen by 1.0%, selling 50,246 shares and leaving it with 4,993,945 shares (about 8.87% of the company) valued at $818.3 million.
• Q4 results beat estimates—EPS $0.49 vs. $0.44 and revenue $197.9M (up 18.1% year-over-year)—and Repligen set FY2026 guidance of 1.930–2.010 EPS (analysts expect ~1.97).
• Institutional ownership is very high at 97.64%; shares opened at $117.20 (market cap $6.61B) and analysts hold a consensus "Moderate Buy" rating with an average target of $170.25.

Vanguard Group Inc. lowered its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,993,945 shares of the biotechnology company's stock after selling 50,246 shares during the quarter. Vanguard Group Inc. owned about 8.87% of Repligen worth $818,308,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of RGEN. United Capital Financial Advisors LLC acquired a new stake in Repligen during the third quarter valued at approximately $368,387,000. Massachusetts Financial Services Co. MA acquired a new stake in Repligen during the fourth quarter valued at approximately $199,176,000. Balyasny Asset Management L.P. raised its stake in Repligen by 390.6% during the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company's stock valued at $102,557,000 after buying an additional 610,837 shares in the last quarter. Congress Asset Management Co. raised its stake in Repligen by 241.4% during the fourth quarter. Congress Asset Management Co. now owns 746,306 shares of the biotechnology company's stock valued at $122,290,000 after buying an additional 527,714 shares in the last quarter. Finally, Holocene Advisors LP grew its position in shares of Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company's stock valued at $184,077,000 after buying an additional 440,290 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Trading Down 0.9%

Shares of NASDAQ RGEN opened at $117.20 on Friday. The company has a market cap of $6.61 billion, a price-to-earnings ratio of 137.88, a price-to-earnings-growth ratio of 2.28 and a beta of 1.09. Repligen Corporation has a 12-month low of $109.50 and a 12-month high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The stock's 50 day simple moving average is $121.56 and its 200 day simple moving average is $144.70.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business's revenue was up 18.1% on a year-over-year basis. During the same quarter last year, the business posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts expect that Repligen Corporation will post 1.97 EPS for the current year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of recent research reports. Barclays lowered their price objective on shares of Repligen from $175.00 to $145.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. Weiss Ratings cut shares of Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a report on Tuesday, March 3rd. UBS Group dropped their price target on Repligen from $200.00 to $195.00 and set a "buy" rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Saturday, February 28th. Finally, KeyCorp reissued an "overweight" rating on shares of Repligen in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.25.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.